Get startedLog in
    Picture of Aptose Biosciences logo

    APTOF — Aptose Biosciences News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapMomentum Trap
    All News

    Brief: Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval To Dose Escalate In Phase 1/2 Tuscany Trial Of Frontline Triple Drug Therapy With Tuspetinib Amid Complete Responses And Favorable Safety In First Cohort

    Picture of Aptose Biosciences logoAptose Biosciences
    20/02/2025 12:38
    Feb 20 (Reuters) - Aptose Biosciences Inc  APS.TO :
    * APTOSE ANNOUNCES POSITIVE CLINICAL SAFETY REVIEW COMMITTEE
(CSRC) APPROVAL TO DOSE ESCALATE IN PHASE 1/2 TUSCANY TRIAL OF
FRONTLINE TRIPLE DRUG THERAPY WITH TUSPETINIB AMID COMPLETE
RESPONSES AND FAVORABLE SAFETY IN FIRST COHORT
    * APTOSE BIOSCIENCES INC - TUS+VEN+AZA TRIPLET ACHIEVES
COMPLETE
RESPONSES IN DIFFICULT-TO-TREAT AML PATIENTS
    * APTOSE BIOSCIENCES INC - NO SIGNIFICANT SAFETY CONCERNS OR
DOSE
LIMITING TOXICITIES REPORTED
    * APTOSE BIOSCIENCES INC -NO DOSE REDUCTIONS TO
STANDARD-OF-CARE
COMPONENTS OF REGIMEN (AZA/VEN) IN FIRST COHORT

Source text:  ID:nGNX3ssXCD 
Further company coverage:  APS.TO 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Aptose Biosciences

    See all news